menu search

DMTTF / Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25

Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25
LONDON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces that it will release top-line data from its Phase IIa trial of SPL026 in Major Depressive Disorder (“MDD”) prior to market-open tomorrow on Wednesday, January 25, 2023. Read More
Posted: Jan 24 2023, 16:00
Author Name: GlobeNewsWire
Views: 101974

DMTTF News  

Small Pharma to Present at Cowen's 43rd Annual Health Care Conference

By GlobeNewsWire
March 1, 2023

Small Pharma to Present at Cowen's 43rd Annual Health Care Conference

Company will also host a cocktail reception on Tuesday, March 7 Company will also host a cocktail reception on Tuesday, March 7 more_horizontal

Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25

By GlobeNewsWire
January 24, 2023

Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25

LONDON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology comp more_horizontal

Small Pharma to Participate in Upcoming September Investor Conferences

By GlobeNewsWire
September 8, 2022

Small Pharma to Participate in Upcoming September Investor Conferences

LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology com more_horizontal

Canaccord Genuity repeats 'Speculative Buy' rating and $1.00 price target on Small Pharma following publication of its full-year results

By Proactive Investors
June 13, 2022

Canaccord Genuity repeats 'Speculative Buy' rating and $1.00 price target on Small Pharma following publication of its full-year results

Canaccord Genuity (TSX:CF, LSE:CF) analysts have repeated a 'Speculative Buy' rating and $1.00 price target on Small Pharma Inc (TSX-V:DMT, OTCQB:DMT more_horizontal

Small Pharma To Present at the Jefferies Healthcare Conference in New York City on June 10, 2022

By GlobeNewsWire
May 30, 2022

Small Pharma To Present at the Jefferies Healthcare Conference in New York City on June 10, 2022

LONDON, May 30, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology compa more_horizontal


Search within

Pages Search Results: